Reactions Weekly

, Volume 1710, Issue 1, pp 177–177 | Cite as


Various toxicities: case report
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 42-year-old man developed rhabdomyolysis and necrotising myopathy while receiving interleukin-2, ipilimumab and pembrolizumab. Additionally, he developed hypotension, sinus tachycardia, oliguria, metabolic acidosis, and acute kidney injury while receiving interleukin-2 [not all routes, dosages, duration of treatments to reactions onsets and outcomes stated].

The man, who had metastatic malignant melanoma, started receiving ipilimumab. After four doses of systemic ipilimumab, post-treatment imaging showed disease progression. Subsequently, he was enrolled in a genetically engineered T-cell trial. He received a conditioning regimen of fludarabine and cyclophosphamide, which was followed by low dose IV interleukin-2 at a dose of 72000 U/kg every 8 hours. Due to further disease...


  1. Clark JI, et al. Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: A case report. Journal for ImmunoTherapy of Cancer 6: 53, No. 1, 14 Jun 2018. Available from: URL: - USA

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations